Prostate cancer is the second most common cancer in men worldwide [1] , and is the fifth leading cause of cancer death in men with 307,500 deaths in 2012 [1] . Approximately twothirds of prostate cancer cases are disproportionately diagnosed in the developed world, largely due to prostate cancer screening practices [1] . However, some detected cancers are so low grade and slow growing that they are unlikely to affect the individual in his lifetime [2] . Treatment with radical prostatectomy, brachytherapy, or external bean radiotherapy carries risks including erectile dysfunction and urinary incontinence [2] . Differentiation of high-risk disease from indolent tumours can avoid unnecessary aggressive treatment for early stage screening-detected prostate cancers. Prostate cancer management should therefore be directed to the detection and treatment of clinically significant prostate cancer, to reduce mortality rates, while avoiding overdiagnosis and overtreatment.
The current widely accepted best means of detecting prostate cancer is the nontargeted or systematic transrectal ultrasound (TRUS) biopsy; however, this has a false negative rate of 10%-20% [2] , particularly for lesions in the anterior gland, transition zone (TZ), and apex, which are likely to be undersampled. Furthermore, following radical prostatectomy, 30%-45% of patients are upgraded on final pathology to higher-grade tumours compared with their initial diagnoses by nontargeted TRUS [3] . Multiparametric prostate magnetic resonance (MRI) imaging has been shown to be effective in the detection of clinically significant prostate cancer, with improved sensitivity compared with systematic TRUS [4] and comparable results to template prostate mapping biopsies [5] . The multiparametric MRI Prostate Imaging-Reporting and Data System (PI-RADS) was introduced in 2012 [6] to standardize prostate MRI reporting across institutions and reduce the ambiguity of results amongst radiologists and urologists. These guidelines were revised and updated by a steering committee in 2014, with the release of PI-RADS version 2 [7] . A final PI-RADS score is assigned to reflect the likelihood of clinically significant cancer ranging from PI-RADS category 1 (clinically significant cancer is highly unlikely to be present) to category 5 (clinically significant cancer is highly likely to be present) [7] , as detailed in Figure 1 .
PI-RADS lesions can be targeted with MRI-US fusion biopsy or in-bore MRI biopsy for more accurate histological evaluation of the gland, with the overall aim of more appropriately directed prostate carcinoma management. MRI-TRUS fusion biopsy involves digital fusion of a previously performed multiparametric MRI with real-time TRUS scanning, allowing the user to biopsy MRI-detected target lesions that are often occult on TRUS. Although PI-RADS 4 and 5 lesions typically proceed for tissue diagnosis due to the high carcinoma likelihood, the decision tree involving category 3 lesions, which are equivocal for the presence of clinically significant carcinoma, is less clear. This study examines the characteristics and histological outcomes of biopsied lesions to assess the performance of the PI-RADS system at our institution, with an aim to direct future use, particularly regarding the management of equivocal PI-RADS 3 lesions.
Materials and Methods
Our institutional review board approved this retrospective study, with the requirement for written informed consent waived. Between January 2015 (time of incorporation of PI-RADS version 2 as the standard for reporting at our institution) and June 2016 (endpoint of available data at the time of data collection) all MRI-US prostate fusion biopsies were reviewed. Men with prior focal therapy or imaging which did not meet the PI-RADS version 2 technical standards were excluded. For those with multiple biopsied lesions that were PI-RADS category 3 or greater, each lesion was included in the study.
Multiparametric MRI studies were performed using pelvic phased array coils on 1.5T (144 of 194; 74.2%) or 3.0T (50 of 194; 25.8%) MRI systems, without the use of an endorectal coil. Sequences included axial, sagittal, and coronal T2weighted images encompassing the entire prostate gland and seminal vesicles; axial diffusion-weighted imaging (DWI) with b strengths of 50, 500, 1000, and 1500 along with the corresponding apparent diffusion coefficient map; axial T1 images of the entire pelvis; and axial dynamic contrast enhanced (DCE) images with Gadovist (Bayer Healthcare Pharmaceuticals, Montville, NJ) along with subtraction images.
All images were interpreted according to PI-RADS version 2 by subspecialized abdominal radiologists, with experience in prostate MRI interpretation ranging between 2-15 years. MRI findings were again reviewed before performing fusion biopsy, with the documentation of a PI-RADS score for each sequence, dichotomous DCE result (positive or negative), and the overall PI-RADS score. External referrals were discussed at the monthly multidisciplinary prostate rounds, where consensus decisions were made regarding lesions requiring biopsy. Transrectal fusion biopsies were obtained via an MRI-TRUS Figure 1 . Summary of Prostate Imaging-Reporting and Data System (PI-RADS) version 2 scoring system, adapted from PI-RADS version 2 document from the American College of Radiology [7] . ADC ¼ apparent diffusion coefficient; CSC ¼ clinically significant carcinoma; DCE ¼ dynamic contrast enhancement; DWI ¼ diffusion-weighted imaging; EPE ¼ extraprostatic extension. fusion system (Sentinelle Medical, Toronto, Ontario, Canada), with biopsies performed by genitourinary radiologists. At least 2 targeted core biopsies were obtained per lesion. Systematic cores biopsies were obtained following fusion targets, in the same sitting as follows: 8 cores for gland volume <30 cm 3 , 10 cores for 30-60 cm 3 gland volume, and 12 cores for gland volume >60 cm 3 . Specialized genitourinary pathologists reviewed the histopathology.
Statistical analysis was performed using statistical software IBM SPSS version 24 (IBM Corp, Armonk, NY). Prostate-specific antigen (PSA) density was dichotomized into 0.15 or >0.15 ng/mL/cm 3 , as this value has been shown to be helpful in the differentiation of clinically significant disease [8] . T2 and DWI scores were categorized into 3 groups for statistical analysis: a score of 1 or 2, 3, and 4 or 5. Although various definitions of clinically significant carcinoma exist, we defined any cancer with a grade group of 2-5 (ie, Gleason score 3 þ 4 ¼ 7 or greater) as clinically significant in this study. Secondarily, we also considered patients with grade group 3-5 (ie, Gleason 4 þ 3 ¼ 7 or greater) tumours separately, as an increasing number of lowvolume-grade group 2 patients are being included in active surveillance regimens. Chi-square and Fisher exact tests were used for comparison of categorical variables, as appropriate. A P value <.05 was chosen to represent statistical significance.
Results

Study Population and Patient Characteristics
MR-TRUS fusion biopsy of the prostate was performed in 215 men at our institution over the study period. Nine men had external imaging that was no longer available for review to ensure adequate technical specifications, and hence were excluded. Another 9 men had suboptimal MR studies according to PI-RADS version 2, including those with severe hip implant artifacts. One individual had prior focal therapy and was excluded. Two men appeared to have been mistargeted on review of procedural images and were sent for rebiopsy. Of the remaining 194 men, 64 had multiple lesions biopsied, resulting in a total of 269 biopsied lesions ( Figure 2 ), of which 128 were category 4 and 5 lesions and 141 were category 3 lesions.
The cohort of 194 men ranged from 42-83 years of age, with a mean of 65 years of age. The mean PSA was 10.5 ng/ mL and the mean prostate volume was 53.3 cm 3 ( Table 1) . The PSA density (PSAD) was >0.15 ng/mL/cm 3 in 55.7% (108 of 194) of patients.
The majority of men had a previous prostate biopsy, with 45.9% (89 of 194) of the study population on active surveillance for clinically insignificant carcinoma, none of whom had grade group 2 or greater disease. A slightly smaller proportion of men (42.3%, 82 of 194) had prior negative biopsies, with just under 12% (23 of 194) of the sample representing biopsy-naive men.
Characteristics of Biopsied Lesions
PI-RADS category 3 lesions were the most commonly biopsied (52.4%), followed by category 4 (30.5%) and category 5 lesions (17.1%). There was a strong correlation between overall PI-RADS score and histological outcomes (P < .01), with clinically significant disease more likely to be present with increasing PI-RADS score ( Table 2) .
Just over half the biopsied lesions were in the TZ (52.8%). A greater proportion of PI-RADS category 3 lesions were located in the TZ (62.4%) than in the peripheral zone (PZ) (37.6%). Lesions were fairly evenly distributed between the anterior (50.6%) and posterior (49.4%) halves of the gland. Just over half of lesions were located in the midgland (55.0%), followed by apical (26.0%) and basal (19.0%) locations. There was no correlation between lesion location and histological outcomes (P > .05 for all). The majority of lesions (78.1%, 210 of 269) were <1.5 cm in size.
Imaging Characteristics
There was strong correlation between T2 score and DWI score with histological outcomes, irrespective of location 
Histology Results
All lesions
Targeted biopsy revealed no carcinoma in 41.6% (112 of 269) and any carcinoma in 58.3% (157 of 269). Grade group !2 carcinoma was found in 36.4% (98 of 269), with slightly more than half (50 of 98) of these grade group !3 and just under half (48 of 98) grade group 2. A PSAD of >0.15 resulted in grade group !2 in 51.9% compared with only 30.2% of those with a PSAD 0.15 (P ¼ .01).
PI-RADS 3 lesions
Targeted biopsy revealed no carcinoma in 64.5% (91 of 141) and any carcinoma in 35.5% (50 of 141) of PI-RADS 3 lesions (Table 2 ). Grade group !2 carcinoma was found in 15.6% (22 of 141), with 72.7% of these being grade group 2 and 27.3% being grade group !3. There was no correlation among PSAD, lesion size, T2 score, DWI score, or DCE result and PI-RADS category 3 lesion histological outcomes (P > .05 for all).
The presence of a category 4 or 5 lesion elsewhere in the prostate did not increase the risk of PI-RADS category 3 lesion malignancy (P > .05). In PI-RADS 3 lesions, grade group !2 disease was more common in the PZ (12 of 53, 22.6%) compared with in the TZ (8 of 88, 9.1%; P ¼ .02), with a higher proportion of biopsy negative TZ lesions (72.7%) compared with PZ lesions (50.9%) ( Figure 3 ).
In patients who had a prior biopsy, category 3 lesions were more likely to represent grade group !2 disease in men on active surveillance (12 of 69, 17.4%), compared with men with a previous negative biopsy (5 of 59, 8.5%; P < .01) ( Figure 4 ).
PI-RADS 4 and 5
Any carcinoma was detected in 42 of 46 (91.3%) of category 5 lesions, with grade group !2 disease in 67.4% (31 of 46). PI-RADS 4 lesions yielded any carcinoma in 65 of 82 (79.3%) of cases, with 54.9% (45 of 82) of these being grade group !2 disease (Table 2 ). The category 4 and 5 lesions that harbored no cancer in targeted biopsy (n ¼ 21) were reviewed retrospectively. Nine of these lesions were PZ lesions upgraded to category 4 based on DCE. Five lesions were at the border of the TZ and PZ, with difficulty in definitively ascribing the precise anatomic location. Three lesions were retrospectively thought to represent central zone asymmetry (ie, an anatomic variant), rather than true pathology. The remaining 4 lesions were again assessed as direct category 4 or 5, hence representing false positive MRI lesions.
Nontarget cores
Nontarget cores were negative for carcinoma in 57.7 % (112 of 194) of men, with grade group 1 disease found in 15.5% (30 of 194) and grade group !2 in 26.8% (52 of 194). All of the men with grade group !2 disease detected in nontarget cores also showed grade group !2 tumour on target core histology ( Figure 5 ). There was no correlation with lesion location within the PZ or TZ or previous biopsy results and nontarget core histology. Positive nontarget cores were noted to be within prostate sectors adjacent to the MRI fusion target in the majority of men (70.7%; 58 of 82). Increasing target lesion PI-RADS score increased the likelihood of clinically significant disease in nontarget cores (P < .01).
For the targeted index lesions that were benign, 96.9% (63 of 65) of these had corresponding biopsy-negative nontarget cores. The remaining 2 men with positive systematic cores but negative target biopsies both showed grade group 1 disease. Nearly two-thirds (63.4%) of men with grade group !2 disease in target cores also showed grade group !2 disease in nontarget cores. In men with clinically significant targeted biopsies, 25.6% had negative systematic cores, hence indicative of the increased accuracy of prostate MRI-targeted biopsy over nontargeted systematic biopsy ( Figure 5 ).
Discussion
In this study, the overall PI-RADS score correlated well with histological outcomes, lending further validation to the PI-RADS version 2 classification.
Although most category 3 lesions are benign or clinically insignificant disease, the approximately 1-in-6 chance of grade group !2 carcinoma demonstrated in this study warrants consideration for tissue diagnosis. A prior PI-RADS version 2 study revealed grade group !2 disease in 11.4 to 27.1% of PI-RADS category 3 lesions [9] . Our study revealed that category 3 lesions were more likely to yield clinically significant disease in men on active surveillance. An older retrospective study using PIRADS version 1 also demonstrated a higher positivity rate of category 3 lesions in men with prior positive biopsy results [10] . In the multidisciplinary discussion of the necessity of biopsy of category 3 lesions; therefore, a lower threshold for proceeding to tissue diagnosis should be placed in men on active surveillance ( Figure 6 ). It is of note, however, that only 4.3% of category 3 lesions yielded grade group !3 disease. If grade group 1 or 2 disease is unlikely to lead to intervention in an individual patient, the minimal yield of higher grade carcinoma means that the benefits versus risk of biopsy must be carefully considered.
PZ category 3 lesions were also more likely grade group !2 disease compared with TZ lesions, with a greater proportion of benign TZ category 3 lesions compared with those in the PZ. In our experience, assessment of the TZ often proves more subjective and challenging compared with the PZ, largely due to the heterogeneity and multinodularity typically encountered in TZ hypertrophy. Often there is suspicion of a TZ lesion representing a benign prostatic hyperplasia (BPH) nodule; however, as the margins may be obscured due to the mass effect within a multinodular TZ, a PI-RADS category 3 score is the result. A study of the interobserver reproducibility of the PI-RADS version 2 lexicon demonstrated better agreement of overall PI-RADS assessment categories in PZ lesions compared with TZ lesions [11] . Future PI-RADS versions therefore warrant greater clarification and refinement of rules for TZ lesions, in the differentiation of BPH nodules. A recent paper by Rosenkrantz et al [9] proposed morphologic DCE criteria for the differentiation of equivocal TZ lesions where encapsulated swirled or popcorn-like enhancement was more suggestive of BPH compared with the more suspicious finding of unencapsulated sheet-like confluent enhancement.
PI-RADS category 4 and 5 lesions were associated with a 54.9% and 67.4% yield, respectively, of grade group !2 disease in our study. Reported literature states a clinically significant prostate carcinoma rate of 44.4%-49.3% for category 4 and 72.1%-73.7% for category 5 lesions [9] . Review of our biopsy-negative category 4 lesions showed a number of these to be PZ lesions, upgraded by DCE positivity. Although not specifically examined in this paper, prior studies have shown that upgraded PZ category 3 lesions are less likely to yield clinically significant disease compared with direct category 4 lesions [12] , with upgraded lesions resulting in grade group !2 tumour in approximately onethird of patients [9] . Radiologists must therefore endeavor to specifically communicate upgrades versus direct category lesions in the multiparametric MRI report. Urologists must also be made aware of the differences in the diagnostic yield between these groups. In individual cases the treating physician could decide against biopsy of a PI-RADS 3þ1 lesion.
Review of our biopsy negative category 4 and 5 lesions also demonstrated lesions in which there was anatomic ambiguity. Lesions may be present at an anatomic border, without clear assignment to a single anatomic zone. This can sometimes be challenging even to experienced readers. As the PI-RADS assessment hinges on the lesion's anatomic location, ambiguity can result in errors in assigning a score. Visualization of these lesions in all 3 planes is paramount for ascribing the most accurate anatomic zone possible (Figure 7) . Future PI-RADS editions must clarify assignment of anatomic zones for these particular lesions, whether by assessment of the epicenter or location of >50% of the lesion [13] . Knowledge of anatomic variants is paramount to prostate MRI interpretation, as central zone asymmetry was another source of uncertainty noted on our review. The DCE sequence can aid in the differentiation of normal variant asymmetry of the central zone or anterior fibromuscular stroma versus true lesions. For anomalies identified in these locations, a type 3 washout enhancement pattern is more likely indicative of a true lesion compared with the normal variant finding [14, 15] .
Given the probability of PI-RADS category 4 and 5 lesion positivity, biopsy-negative category 4 and 5 lesions should be reviewed at multidisciplinary rounds, from both a radiological and a urological perspective. Prostatitis can be a cause of an unexpected biopsy-negative lesion as it may be indistinguishable from prostate carcinoma on multiparametric MRI [16] ; however, this should be evident on histology results. Given the imperfect registration between MRI and TRUS [17] , the possibility of a missed target lesion must also be considered; hence rebiopsy is warranted if the clinical suspicion remains high.
The increased yield of higher-grade disease in targeted versus systematic cores, as shown in this study, is a known benefit of prostate MRI imaging. This has prompted some authors to suggest targeting of MRI-detected lesions, with the exclusion of systematic cores [18] . Prostate MRI and fusion biopsy are however not without limitations, with reports of between 0%-23% of clinically significant cancers missed by target biopsy but detected by systematic biopsies [19] . Even in the setting of optimal MRI protocols and experienced readers, about 5% of clinically significant tumours are noted to be MRI occult, usually when a sparse tumour growth pattern is encountered histologically [20] . Imperfect fusion is another factor that may lead to false negative target lesions. In this dataset, no patient was upgraded to grade group !2 disease with the inclusion of nontarget cores; however, when considering the data from prior studies, omission of systematic core biopsies may result in an unacceptable number of missed clinically significant tumours in the wider population [21] . Bjurlin et al [22] noted that the likelihood of clinically significant carcinoma detected on systematic cores that was missed on targeted cores decreased with increasing operator experience. The recommendation therefore to always include concurrent systematic biopsies may depend on institutional experience with MRI-US fusion biopsy.
Study Limitations
Given the fairly recent introduction of PI-RADS version 2, these data represent a relatively large cohort from a tertiary academic centre. However, the data are limited by their retrospective nature. Reporting radiologists were not blinded to clinical information such as PSA levels or prior biopsy results, as this information is usually accessible in daily practice; however, this does represent a source of potential bias. It is likely that radiologist experience may influence levels of confidence in ascribing PI-RADS scores. Future studies considering interobserver reproducibility and reader confidence are therefore warranted.
Although category 4 and 5 lesions typically proceed for tissue diagnosis, it is estimated that just under half of category 3 lesions at our institution are sent for a biopsy based on clinical grounds. Lower-risk patients with category 3 lesions are therefore less likely to be biopsied and hence may be under-represented in this sample. If all category 3 lesions were biopsied, it is likely that the rate of clinically significant disease would be lower than the results obtained in this study.
Fusion biopsy, although more reliably accurate than systematic or cognitive biopsy [23] , does carry the possibility of undersampling when compared with the gold standard of radical prostatectomy. There is a measure of deformation of the gland on TRUS biopsy due to the application of probe pressure, resulting in possible inaccuracies with MRI fusion [17] . However, as fusion biopsy technology advances, such as with improved elastic registration methods, this is likely to become less problematic. Figure 7 . (A) Axial T2, (B) coronal T2, and (C) sagittal T2 sequences in a 71-year-old man, prior biopsy negative, with a T2 hypointense lesion noted at the extreme right apex anteriorly (arrows). At this position in the apex, peripheral zone tissue would be expected; however, it is effaced due to marked transition zone hypertrophy. Coronal and sagittal images show that this lesion is bound by the pseudocapsule, hence it is within the transition zone. The margins are partially circumscribed but partially obscured. Prostate Imaging-Reporting and Data System (PI-RADS) category 3 finding. This lesion was initially incorrectly classified as peripheral zone in origin, with a PI-RADS category 4 (3 þ 1) score. Targeted biopsy of the previously described lesion as well as 2 other PI-RADS category 3 transition zone findings were negative for carcinoma.
Conclusions
PI-RADS version 2 has proven to be effective in the detection of clinically significant prostate carcinoma, resulting in more accurate and appropriate patient management. As software advances and institutional experience increases, prostate fusion biopsy outcomes are likely to become increasingly more precise. Clinicians must be aware of the rate of category 3 lesion positivity, with greater emphasis placed on lesions located in the PZ and in men on active surveillance. As management recommendations are currently not ascribed to PI-RADS categories, this remains best decided in a multidisciplinary setting. There must be communication between radiologists and urologists regarding the lower than expected yield of upgraded category 4 PZ lesions, as noted in the literature. Radiologists must also be aware of the possible pitfalls in assessing lesions at anatomic borders or in the setting of variant anatomy. Continued feedback and dialogue between radiologists and urologists is likely to improve the functioning of the PI-RADS system within and across institutions, as the practice of multiparametric MRI and prostate fusion biopsy continues to evolve.
